What is the outpatient management for a low‑risk adult with community‑acquired pneumonia who is hemodynamically stable, can take oral medication, has no significant comorbidities, no recent antibiotic use, and no immunosuppression?

Management of Low-Risk Community-Acquired Pneumonia

For a previously healthy adult with low-risk community-acquired pneumonia and no recent antibiotic use, treat with oral amoxicillin 1g three times daily, doxycycline 100mg twice daily, or a macrolide (azithromycin or clarithromycin) for a minimum of 5 days. 1

Risk Stratification and Site of Care

• Low-risk patients (PSI risk classes I, II, and III) should be managed as outpatients unless there are preexisting conditions that compromise safety of home care or clinical judgment suggests otherwise 1
• These patients are hemodynamically stable, can take oral medications, have no significant comorbidities, and meet criteria for outpatient management 1

First-Line Antibiotic Selection

For Previously Healthy Patients Without Recent Antibiotic Use:

Monotherapy options include: 1

• Amoxicillin 1g three times daily (preferred beta-lactam option) 1
• Doxycycline 100mg twice daily 1
• Macrolide monotherapy (azithromycin 500mg on day 1, then 250mg daily for 4 days; OR clarithromycin 500mg twice daily) 1

Important Caveat on Macrolide Use:

• Macrolide monotherapy should only be used in areas where local pneumococcal resistance is <25% 1
• In areas with higher resistance rates, choose amoxicillin or doxycycline instead 1
• This is a critical consideration given rising pneumococcal resistance patterns 2, 3

Treatment Duration

• Minimum treatment duration is 5 days 1
• Patients should be afebrile for 48-72 hours before discontinuing therapy 1
• No more than 1 sign of clinical instability should be present at discontinuation 1
• Treatment for at least 7 days is recommended by some guidelines, except when using azithromycin or clarithromycin which have shorter courses 1

Clinical Monitoring and Follow-Up

Assessment of Response:

• Clinical improvement should be evident within 3-5 days of initiating therapy 1
• Assess response at day 5-7 by evaluating improvement of symptoms (reduced fever, improved cough, decreased dyspnea) 1
• Chest radiograph changes typically lag behind clinical improvement and repeat imaging is not routinely needed for responding patients 1

Follow-Up Care:

• Clinical review should be arranged at approximately 6 weeks with either the general practitioner or hospital clinic 1
• Chest radiograph at 6 weeks is indicated for: 1
  • Patients with persistent symptoms or physical signs
  • Those at higher risk of underlying malignancy (especially smokers and those over 50 years)

Common Pitfalls to Avoid

Antibiotic Selection Errors:

• Do not use fluoroquinolones as first-line agents in low-risk outpatients 1
• Fluoroquinolones should be reserved for patients with comorbidities or recent antibiotic use to preserve their effectiveness and minimize resistance 1, 3
• Avoid macrolide monotherapy in areas with high pneumococcal resistance (≥25%) 1

Inappropriate Hospitalization:

• Do not hospitalize patients who meet low-risk criteria solely for observation while on oral antibiotics 1
• Outpatient management is safe and appropriate for PSI risk classes I-III 1

Overtreatment:

• Do not routinely perform microbiologic testing (sputum culture, blood cultures) in low-risk outpatients 1, 4
• These tests are not cost-effective and do not change management in uncomplicated outpatient cases 1
• Do not routinely test for pneumococcal or Legionella urinary antigens in low-risk outpatients 1

When to Consider Alternative Regimens

If Recent Antibiotic Use (within 90 days):

• Use combination therapy: respiratory fluoroquinolone alone OR advanced macrolide plus high-dose amoxicillin (or amoxicillin-clavulanate) 1
• This accounts for potential antibiotic resistance from recent exposure 1

If Comorbidities Present:

• Comorbidities include: COPD, diabetes, renal failure, congestive heart failure, or malignancy 1
• Preferred regimens: combination therapy with amoxicillin/clavulanate or cephalosporin PLUS macrolide or doxycycline, OR monotherapy with respiratory fluoroquinolone 1

Diagnostic Testing Considerations

• Test for COVID-19 and influenza when these viruses are common in the community, as their diagnosis may affect treatment and infection prevention strategies 2
• If viral testing is negative, proceed with empirical antibacterial therapy as outlined above 2